Dr. Barry Borlaug and Dr. C. Michael Gibson Discuss: CAMEO-DAPA Trial: Evaluation of the Mechanism of Benefit For Dapagliflozin in Heart Failure With Preserved Ejection Fraction: An Invasive Hemodynamic Randomized Trial March 6, 2023 Disclosures: TBD
Dr. Hyo-Soo Kim and Dr. C. Michael Gibson Discuss: Comparison of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-eluting Stents With Ultrathin Struts And Advanced Polymer Technology: The HOST-IDEA Randomized Clinical Trial March 5, 2023 Disclosures: TBD
Dr. Gregg Stone and Dr. C. Michael Gibson Discuss: Transcatheter Edge-to-edge Repair of Functional Mitral Regurgitation in Heart Failure: Final Five-year Results From the COAPT Trial March 5, 2023 Disclosures: TBD
Dr. Enoch Akowuah and Dr. C. Michael Gibson Discuss: Minimally Invasive Versus Conventional Sternotomy For Mitral Valve Repair Surgery: An Expertise Based Multicentre Randomised Controlled Trial (UK Mini Mitral) March 5, 2023 Disclosures: TBD
Dr. Divaka Perera and Dr. C. Michael Gibson Discuss: Effect of Myocardial Viability, Percutaneous Coronary Intervention and Functional Recovery on Clinical Outcomes in the REVIVED-BCIS2 Randomized Trial March 4, 2023 Disclosures: TBD
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: Bempedoic Acid And Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk March 4, 2023 Disclosures: TBD
Dr. David Kandzari and Dr. C. Michael Gibson Discuss: SPYRAL HTN-ON – Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results from the SPYRAL HTN-ON Med Expansion Randomized Trial November 7, 2022 Disclosures: TBD
Dr. James Jollis, Dr. Jacqueline Tamis-Holland, and Dr. C. Michael Gibson Discuss: Treatment Time and In-Hospital Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-2021 November 7, 2022 Disclosures: TBD
Dr. Dominick Angiolillo Presents: From Dual Antiplatelet Treatment Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition With Low-Dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease: The SWAP-AC Study November 7, 2022 Disclosures: TBD
Dr. Dominick Angiolillo Presents: Pharmacodynamic and Pharmacokinetic Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-Treatment: The SWAP-5 Study November 7, 2022 Disclosures: TBD
